Tokai Pharmaceuticals Appoints Daniel T. Dransfield, Ph.D. as Vice President, Head of Translational Medicine

  Tokai Pharmaceuticals Appoints Daniel T. Dransfield, Ph.D. as Vice
  President, Head of Translational Medicine

Business Wire

CAMBRIDGE, Mass. -- August 27, 2014

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing
novel therapies for prostate cancer and other hormonally-driven diseases,
today announced the appointment of Daniel T. Dransfield, Ph.D. as vice
president and head of translational medicine. Dr. Dransfield, formerly vice
president of discovery research and translational medicine at ArQule, Inc.,
brings more than 20 years of drug development and research experience to
Tokai.

“We are very pleased to welcome Dan to the Tokai team,” said Jodie Morrison,
president and chief executive officer, Tokai Pharmaceuticals. “Dan’s
experience and expertise in the preclinical development of anti-cancer agents
and the development of companion diagnostics adds additional strength to our
management team. We expect Dan will play key roles in the company’s program to
develop a diagnostic for patient selection in our planned pivotal trial as
well as the identification and evaluation of drug candidates within our
Androgen Receptor Degrading Agents (ARDA) platform.”

At ArQule, Dr. Dransfield held vice president positions in discovery research,
translational medicine and kinase biology since 2012, where he supervised
multiple teams of scientists that evaluated therapeutic candidates, shaping
the company’s clinical programs and development strategy. Prior to his
positions at ArQule, Dr. Dransfield spent 11 years at Dyax Corporation in
roles of increasing responsibility, culminating as vice president of cell
biology and translational research. Prior to Dyax, he worked for nearly a
decade in various instructor and scientist roles at the Institute of Molecular
Medicine & Genetics, Medical College of Georgia. Dr. Dransfield has authored a
number of peer-reviewed papers, is an active participant in professional
oncology associations and is the holder of several patents. He has a B.S. in
biology from The Catholic University of America and a Ph.D. from Tufts
University.

About Galeterone

Galeterone is a highly selective, multi-targeted, oral small molecule drug
candidate being developed for the treatment of castration-resistant prostate
cancer that acts by actively disrupting androgen receptor (AR) signaling, the
key driver of prostate cancer growth, via multiple mechanisms of action.
Galeterone combines the mechanisms of action of CYP17 inhibition and androgen
receptor antagonism with an additional mechanism of androgen receptor
degradation. Current available therapies disrupt the pathway at a single
point. To Tokai’s knowledge, galeterone is the only drug candidate in clinical
trials that disrupts the pathway at multiple points.

About Tokai Pharmaceuticals

Tokai Pharmaceuticals is a biopharmaceutical company focused on developing
novel therapies for prostate cancer and other hormonally-driven diseases. The
company’s lead drug candidate, galeterone, is a highly selective,
multi-targeted, oral small molecule drug candidate being developed for the
treatment of patients with castration-resistant prostate cancer. The Company’s
ARDA drug discovery platform is focused on the identification and evaluation
of compounds with potent androgen receptor degradation activity targeted to
patients with androgen receptor signaling diseases, including prostate cancer.
Based in Cambridge, Massachusetts, Tokai is backed by Apple Tree Partners,
Novartis Venture Funds, Satter Investment Management, as well as other
investors. For more information on the company and galeterone, please visit
www.tokaipharma.com.

Contact:

Pure Communications, Inc.
Sheryl Seapy, 949-903-4750
 
Press spacebar to pause and continue. Press esc to stop.